¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"adverse drug reaction reporting systems"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • body-righting reaction
    ¸ö¹Ù·ÎÀâ±â¹ÝÀÀ, Á¤Çâ¹ÝÀÀ
  • cadaveric reaction
    ½Ãü¹ÝÀÀ
  • Cannizzaro¡¯s reaction
    Ä­´ÏÂ÷·Î¹ÝÀÀ
  • circular reaction
    ¼øÈ¯¹ÝÀÀ
  • color reaction
    ¹ß»ö¹ÝÀÀ, »öä¹ÝÀÀ
  • capsular precipitation reaction
    ÇǸ·Ä§Àü¹ÝÀÀ
  • capsular swelling reaction
    ÇǸ·ÆØÃ¢¹ÝÀÀ
  • carbamino reaction
    Ä«¸£¹Ù¹Ì³ë¹ÝÀÀ
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ
  • conglutination reaction
    ±³Âø¹ÝÀÀ
  • consensual pupillary reaction
    °ø°¨µ¿°ø¹ÝÀÀ
  • conversion reaction
    Àüȯ¹ÝÀÀ
  • counter reaction
    ¿ª¹ÝÀÀ
  • coupled reaction
    °ø¿ª¹ÝÀÀ, ¦Áø¹ÝÀÀ, ¿¬°á¹ÝÀÀ
  • cross-reaction
    ±³Â÷¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • arm tonus reaction
    À§ÆÈ±ÙÀ°±äÀå¹ÝÀÀ
  • Arthus reaction
    ¾Æ¸£Åõ½º¹ÝÀÀ
  • associated reaction
    ¿¬ÇÕ¹ÝÀÀ
  • autoimmune reaction
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • axon reaction
    Ãà»è¹ÝÀÀ
  • reaction accelerator
    ¹ÝÀÀÃËÁøÃ¼
  • bimolecular reaction
    À̺ÐÀÚ¹ÝÀÀ
  • biologic false positive reaction
    »ý¹°ÇÐÀû°ÅÁþ¾ç¼º¹ÝÀÀ
  • biotelluric reaction
    »ý¹°ÅÚ·ç·ý¿°¹ÝÀÀ
  • biphasic reaction
    À̻󼺹ÝÀÀ
  • bisubstrate reaction
    µÎ±âÁú¹ÝÀÀ
  • biuret reaction
    ºß·¿¹ÝÀÀ
  • blanching reaction
    â¹é¹ÝÀÀ
  • blood transfusion reaction
    ¼öÇ÷¹ÝÀÀ
  • body righting reaction
    ¸öÅë¹Ù·ÎÀâ±â¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • gross stress reaction
    ´ëÀÚ±Ø<ÃÑüÀû½ºÆ®·¹½º>¹ÝÀÀ(ÓÞí©Ð½<õÅô÷îÜ~>Úãëë)
  • group reaction
    Áý´Ü¹ÝÀÀ(̤ËÀËÑËô).
  • heat of reaction
    ¹ÝÀÀ¿­(Úãëëæð).
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemoclastic reaction
    Ç÷±¸ºØ±«¹ÝÀÀ.
  • hemolytic transfusion reaction
    ¿ëÇ÷¼º ¼öÇ÷¹ÝÀÀ.
  • heterogeneous reaction
    ºÒ±ÕÀϹÝÀÀ, ºÒ±ÕÁú¹ÝÀÀ.
  • heterophil(e) antibody reaction
    ÀÌÁ¾Ä£È­(¼º) Ç×ü¹ÝÀÀ(¡­Úãëë).
  • homograft reaction
    µ¿Á¾ÀÌ½ÄÆí¹ÝÀÀ.
  • hyperkinetic reaction
    °ú´Ù¿îµ¿ ¹ÝÀÀ
  • hypersensitive reaction
    °ú¹Î¼º ¹ÝÀÀ(ΦÚÂàõÚãëë).
  • hypersensitivity reaction
    °ú¹Î¹ÝÀÀ
  • hypnic reaction
    ¼ö¸é ¹ÝÀÀ(â²ØùÚãëë)
  • hypnic reaction
    ¼ö¸é¹ÝÀÀ(¡­Úãëë).
  • hysteric reaction
    È÷½ºÅ׸®¼º ¹ÝÀÀ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • drug resistance
    ¾à¹°ÀúÇ×¼º.
  • drug resistance
    ¾àÁ¦³»¼º
  • drug resistance factor
    ¾àÁ¦³»¼ºÀÎÀÚ
  • drug resistance plasmid
    ¾àÁ¦³»¼º Çö󽺹̵å
  • drug resistance transfer factor
    ¾àÁ¦³»¼ºÀü´ÞÀÎÀÚ
  • drug resistant bacterium
    ¾àÁ¦³»¼º¼¼±Õ
  • drug shock
    ¾à¹°Ãæ°Ý(¡­õú̪).
  • drug shop =d. store
    ¾à¹° ÀǾ౹(ËâË´).
  • drug therapy
    ¾à¹° ¾à¹°¿ä¹ý(¡­èþÛö).
  • drug tolerance
    ¾à¹°<¾àÁ¦>³»¼º.
  • drug tolerance
    ¾à¹°³»¼º(å·ÚªÒ±àõ).
  • drug treatment
    ¾à¹°¿ä¹ý(¡­èþÛö).
  • drug urticaria
    ¾à¹° µÎµå·¯±â
  • drug utilization review
    ¾à¹°»ç¿ë °ËÅä.
  • drug withdrawal
    ¾à¹°±Ý´Ü(Ð×Ó¨).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
  • terreactant reaction
    »ï¹ÝÀÀ¹° ¹ÝÀÀ (ß²ÚãëëÚªÚãëë)
  • theory of absolute reaction rates
    Àý´ë¹ÝÀÀ¼Óµµ ÀÌ·Ð (ï¾ÓßÚãëëáÜÓøì¶Öå)
  • thermonuclear reaction
    ¿­ÇÙ¹ÝÀÀ (æðú·Úãëë)
  • thioclastic reaction
    ŸÀÌ¿ÀºÐÇØ (ÝÂú°) ¹ÝÀÀ(Úãëë)
  • third-order reaction
    »ïÂ÷ ¹ÝÀÀ (ß²ó­Úãëë)
  • time constant of a reaction
    ¹ÝÀÀ ½Ã°£»ó¼ö (ÚãëëãÁÊàßÈâ¦)
  • trigger reaction
    ¹æ¾Æ¼è ¹ÝÀÀ(Úãëë)
  • unimolecular reaction
    ÀϺÐÀÚ(ìéÝÂí­) ¹ÝÀÀ (Úãëë)
  • uphill reaction
    ¿À¸£¸· ¹ÝÀÀ (Úãëë)
  • van den Bergh reaction
    ¹Ý µ§ º£¸£±× ¹ÝÀÀ (Úãëë)
  • vectorial reaction
    ÁöÇâ(ò¦ú¾) ¹ÝÀÀ (Úãëë)
  • xanthoproteic reaction
    Ȳ´Ü¹éÁú(üÜÓ±ÛÜòõ) ¹ÝÀÀ(Úãëë)
  • yellow protein reaction
    Ȳ»ö ´Ü¹éÁú(üÜßäÓ±ÛÜòõ) ¹ÝÀÀ (Úãëë)
  • zero-order reaction
    ¿µÂ÷(çÍó­) ¹ÝÀÀ(Úãëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
ACCESS Ambulatory Care Clinic Effectiveness Systems Study; automated cervical cell screening system
COSMIS Computer System for Medical Information Systems
COTH Council of Teaching Hospitals and Health Systems
DBMS data base management systems
GeriROS geriatric review of systems
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 10
IVDU IV drug users
IDU Injecting drug use
IDU Injecting drug users
IDU Injection drug use
IDU Injection drug users
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • biphasic reaction
    ÀÌ»ó¼º ¹ÝÀÀ
  • bisubstrate reaction
    º¹±âÁú ¹ÝÀÀ
  • blanching reaction
    â¹é ¹ÝÀÀ
  • cadaveric reaction
    »çü¾ç ¹ÝÀÀ
    °¡Á·¼º Áֱ⼺ ¸¶ºñ¿¡¼­ º´¿¡ °É¸° ±ÙÀ°ÀÇ Àü±â Àڱؿ¡ ´ëÇÑ ¹ÝÀÀÀÌ ¸ðµÎ ¼Ò½ÇµÇ´Â °Í.
  • cascade reaction
    ÆøÆ÷»ó ¹ÝÀÀ
  • catalytic reaction
    Ã˸йÝÀÀ
    Ã˸ŠÀÛ¿ë¿¡ ÀÇÇØ¼­ È­Çй°ÁúÀÇ ÀÛ¿ëÀ¸·Î ÀϾ´Â Çö»ó.
  • cell mediated reaction
    ¼¼Æ÷ ¸Å°³¼º ¹ÝÀÀ
  • cessation reaction
    Á¤Áö ¹ÝÀÀ
  • chain initiation reaction
    ¿¬¼â °³½Ã ¹ÝÀÀ
  • conjugating reaction
    °áÇÕ ¹ÝÀÀ
  • conjunctival reaction
    °á¸· ¹ÝÀÀ
  • cross reaction
    ±³Â÷ ¹ÝÀÀ
    Ç׿ø Ç×ü ¹ÝÀÀÀÇ °¡Àå Å« Ư¡Àº ÀÌ ¹ÝÀÀÀÌ Æ¯ÀÌÀûÀ̶ó´Â °ÍÀε¥ ¶§·Î´Â ÀÌ ¿øÄ¢¿¡ ¸ÂÁö ¾Ê´Â ¹ÝÀÀÀ» º¸ÀÌ°Ô µÇ´Â ¼ö°¡ ÀÖ´Ù. ¿¹¸¦ µé¾î ¼ÒÀÇ Ç÷û ¾ËºÎ¹Î¿¡ ´ëÇÑ Ç×ü´Â ¾çÀÇ Ç÷û ¾ËºÎ¹Î°úµµ ¾î´À Á¤µµ ¹ÝÀÀÇϴµ¥ ÀÌ °°Àº ¹ÝÀÀÀ» ±³Â÷ ¹ÝÀÀÀ̶ó ÇÑ´Ù.
  • cutaneous reaction
    ÇǺΠ¹ÝÀÀ
  • Dakin-West`s reaction
    µ¥ÀÌŲ-¿þ½ºÆ® ¹ÝÀÀ
  • Dakin`s reaction
    µ¥ÀÌŲ ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 10
drug resistant Unresponsive to the desired effects of drugs or other therapy for example: irradiation cytotoxic agents or hormones. Drug resistance of cells within tumours is probably the major cause of treatment failure.
(16 Dec 1997)
drug screening Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
(12 Dec 1998)
drug screening assays, antitumour Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumour growth parameters in laboratory animals.
(12 Dec 1998)
drug side effect An often undesirable effect that occurs in association with the use of a particular medication.
Examples of common drug side effects include: nausea, vomiting, sedation, dizziness, headache and weakness. Drug side effects that occur in 1% or more, of patients taking a particular medication are considered to be causally related to the use of that medication.
(27 Sep 1997)
drug tetanus Tonic spasms caused by strychnine or other tetanic.
Synonym: toxic tetanus.
(05 Mar 2000)
drug therapy, combination Drug therapy with two or more drugs given separately for a combined effect.
(12 Dec 1998)
drug therapy, computer-assisted Adjunctive computer programs in providing drug treatment to patients.
(12 Dec 1998)
drug, tocolytic A medication that can inhibit labour, slow down or halt the contractions of the uterus. Tocolytic agents are widely used today to treat premature labour and permit pregnancy to procede and so permit the foetus to gain in size and maturity before being born.
(12 Dec 1998)
drug tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from drug resistance wherein a human, animal, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug.
(12 Dec 1998)
drug toxicity The systemic effects of a drug that are related to the overall level of the medication in the bloodstream. Drug toxicity may occur with overdosage of a medication, accumulation of the drug in the body over time or the inability of the patients body to eliminate the drug.
(27 Sep 1997)
drug utilization The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles.
(12 Dec 1998)
drug utilization review Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug utilization review is mandated for medicaid programs beginning in 1993.
(12 Dec 1998)
drug withdrawal A clinical syndrome of psychological, and, sometimes physical factors that result from the sustained use of a particular drug when the drug is abruptly withdrawn.
Symptoms are variable but may include anxiety, nervousness, irritability, sweating, nausea, vomiting, rapid heart rate, rapid breathing and seizures.
(27 Sep 1997)
dyskinesia, drug-induced Abnormal movements induced as an adverse reaction of drug therapy. One particular movement disorder is the "on-off" effect. Tardive dyskinesia differs from akathisia, drug-induced in the repetitive nature of the movements rather than being associated with anxiety, restlessness, and agitation found in akathisia.
(12 Dec 1998)
instillation, drug The administration of therapeutic agents drop by drop, as eye drops, ear drops, or nose drops. It is also administered into a body space or cavity through a catheter. It differs from irrigation in that the irrigate is removed within minutes, but the instillate is left in place.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 10
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 10
ÅëÇÕ°Ë»ö ¿Ï·á